Share

March 2023; 10 (2) Research ArticleOpen Access

CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity

Sasha Gupta, Milos Simic, Sharon A. Sagan, Chanelle Shepherd, Jason Duecker, Raymond A. Sobel, Ravi Dandekar, Gregory F. Wu, Wesley Wu, John E. Pak, Stephen L. Hauser, Wendell Lim, Michael R. Wilson, Scott S. Zamvil
First published January 19, 2023, DOI: https://doi.org/10.1212/NXI.0000000000200080
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
640

Share

Article Information

vol. 10 no. 2 e200080
DOI: 
https://doi.org/10.1212/NXI.0000000000200080
PubMed: 
36657993
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 7, 2022
  • Accepted in final form November 7, 2022
  • First Published January 19, 2023.
Copyright & Usage: 
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Sasha Gupta, MD,
    2. Milos Simic, PhD,
    3. Sharon A. Sagan, BS,
    4. Chanelle Shepherd, BS,
    5. Jason Duecker, BS,
    6. Raymond A. Sobel, MD,
    7. Ravi Dandekar, MS,
    8. Gregory F. Wu, MD, PhD,
    9. Wesley Wu, PhD,
    10. John E. Pak, PhD,
    11. Stephen L. Hauser, MD,
    12. Wendell Lim, PhD,
    13. Michael R. Wilson, MD* and
    14. Scott S. Zamvil, MD, PhD*
  1. Sasha Gupta, MD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I received funding from my fellowship from the National MS Society and Alpha-Stem Cell-CIRM foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Milos Simic, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. None related to this work

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NMSS postodoctoral fellowship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. I have the following stocks::- VIR- MRNA- VBIV- INO- NVAX- REGN- SRNE- BNTX

    Legal Proceedings:

    1. NONE

  3. Sharon A. Sagan, BS,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Chanelle Shepherd, BS,
    5. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jason Duecker, BS,
    6. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Lyell Immunopharma, Research Associate II, 0.5

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Lyell Immunopharma, 0.25

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Raymond A. Sobel, MD,
    7. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Journal of Neuropathology and Experimental Neurology, Deputy Editor, 2017-present,Journal of Neuroimmunology, Associate Editor, 2000-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, R01 NS030843. VK Kuchroo, PI. Role: Co-Investigator, 2010– 2020. NIH, NS108159-01. SS Zamvil, PI. Role: Co-Investigator, 2018-2020 NIH. R01 AI131624. SS Zamvil, PI. Role: Co-Investigator, 2018–2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society (PI: Zamvil)Progressive MS Alliance, administered by National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Ravi Dandekar, MS,
    8. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) University of California, San Francisco

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Gregory F. Wu, MD, PhD,
    9. Scientific Advisory Boards:

    1. 1. Commercial - Genentech2. Commercial - Sangamo

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. editorial board of N2 - no compensation.editorial board of Journal of Neuroimmunology - compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial - GenentechCommercial - Banner LifesciencesGovernment - Department of Justice

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial - EMD Serono, Biogen

    Research Support, Government Entities:

    1. PI, NIH R01NS083678, R21NS121818

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. PI, National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. Progentec

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Government - Department of Justice

  9. Wesley Wu, PhD,
    10. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. John E. Pak, PhD,
    11. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Stephen L. Hauser, MD,
    12. Scientific Advisory Boards:

    1. Serves on scientific advisory board for (1) Accure, (2) Alector, and (3) Annexon; serves on Board of Directors for (4) Neurona.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Harrison's Principles of Internal Medicine,McGraw-Hill Education

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) NGM Bio, (2) Moderna

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. (1) F. Hoffmann La Roche, (2) Novartis AG; travel reimbursement and writing support for anti-CD20 related meetings and presentations.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH, R35NS111644, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Valhalla Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. Stock options received for service on board of directors for (1) Neurona

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Stock options received for service on scientific advisory board for (1) Accure, (2) Alector, (3) Annexon

    Legal Proceedings:

    1. NONE

  12. Wendell Lim, PhD,
    13. Scientific Advisory Boards:

    1. allogene; scifi foods, Burroughs Wellcome Fund

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Cell, Editorial BoardScience, Board of Reviewing Editors

    Patents:

    1. 1. Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors; 2. Synthetic immuno-suppressive cells and methods of use thereof; 3. Therapeutic immune cell circuits for treating Pancreatic Ductal Adenocarcionoma; 4. series of six stable human leukemia (K562) tumor cell lines that differ in amount of HER2-BFP; 5. Chimeric antigen receptors with novel synthetic co-stimulatory domains composed of combinations of linear motifs. 6. Binding triggered regulation of protein degradation; 7. Antigen Explorer: A database of antigen combinations for improving tumor recognition in cancer T cell therapies; 8. Hybrid SynNotch Chimeric Antigen Receptors; 9. USE OF BRAIN-SPECIFIC ANTIGENS TO HOME, BLOCK AND DELIVER THERAPEUTIC TREATMENTS TO THE BRAIN; 10. Engineered Cellular Adhesion Molecules and methods of use thereof; 11. Synthetic receptors and receptor circuits for dual-antigen AND-gate control over expression of a therapeutic payload by engineered cells. 12. Use of MOG for Priming a Treatment for Glioblastoma; 13. A set of tissue-specific receptors to enable a targeted delivery of encoded payloads or cellular responses (cell tissue “GPS” system); 14. Synthetic cytokine circuits to promote targeted local expansion and activation of therapeutic immune cells. 15. A dynamic, autoregulatory circuit to control cytotoxic activity of chimeric antigen receptor cells and improve persistence, efficacy and control; 16.An OFF-switch for regulating synNotch induced cell activity; 17.Methods for regulating the activity of BCL-2 family member proteins in engineered cells to control cell survival/population size; 18. SYSTEMS AND METHODS FOR TARGETING CANCER CELLS; 19. Therapeutic immune cell circuits for treating GBM cancers (focused on EGFRviii negative) by targeting combinatorial antigens; 20.Therapeutic immune cell circuits for treating cancers with antigen heterogeneity; 21. Therapeutic immune cell circuits for treating EGFRviii positive GBM cancers with antigen expression heterogeneity; 22. Antigen density sensors for engineered T cells and their application in cell-based immunotherapies; 23. DNA as a scaffold for efficient and versatile loading of proteins on biodegradable polymeric particles for therapeutic use; 24. Binding-induced proteolytic transcriptional switches engineered using the Von Willdebrand Factor A2 domain as a mechanically regulated proteolytic...; 25. Engineered receptors that associate with the TCR complex to redirect antigen-induced T-cell activation; 26. Engineered receptors and receptor combinations for use in recognition of intracellular antigens; 27. Tumor specific antigen combinations as targets for engineered therapeutic immune cells with multi-antigen detection systems; 28. Chimeric Notch Receptor Platform: modular, engineerable class of contact-dependent cellular receptors in which extracellular inputs can be used to...; 29. A RNA-TARGETED PLATFORM FOR GENETIC PROGRAMMING AND METHODS OF USING SUCH SYSTEM; 30. AN "ON" SWITCH DESIGN AS A PHARMACOLOGICAL METHOD TO CONTROL CHIMERIC ANTIGEN RECEPTOR ACTIVITY FOR CELL-BASED IMMUNOTHERAPIES ("ON-SWITCH CHIMERIC; 31. LIGHT REGULATED SYSTEM FOR THE SPATIOTEMPORAL CONTROL OF SIGNALLING PROTEINS AND THEIR ACTIVITIES; 32. METHOD TO ENGINEER MAPK SIGNALING RESPONSES USING SYNTHETIC SCAFFOLD INTERACTIONS; 33. ENGINEERING DESIGNER PROTEIN SWITCHES USING MODULAR DOMAIN RECOMBINATION

    Publishing Royalties:

    1. Cell Signaling, Garland press, 2014

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NSF, DBI-1548297, co-Inv., 10/2021 – 09/2026NIH/NINDS, R35 NS105068, Inv., 12/2017-11/2025NIH/NCI, R01 CA220257, PI, 09/2018 – 07/2023NIH/NCI, U54CA244438, PI, 09/2019-08/2024Human Frontiers Science Program, RGP0025, co-PI,12/2019-11/2022NIH/NCI, R01 CA249018, PI, 12/2020-11/2026NIH/NCI, R01 CA253017, MPI, 04/2021-03/2027NIH/NCI, U01 CA265697, MPI, 09/2021-08/2026NIH/NCI , U19 CA264338-01, Inv.09/2021-08/2026CIRM, TRAN1-12905, Inv., 01/2022 – 02/2024NIH/NIDDK, R01 DK130969, MPI, 02/2022-01/2026NIH/NIDDK, R01 DK132547-01,MPI, 04/2022-03/2026NIH/NCI, R01 CA258789, PI, 08/2022-07/2027

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. allogene, scifi foods

    License Fee Payments, Technology or Inventions:

    1. 28. Chimeric Notch Receptor Platform: modular, engineerable class of contact-dependent cellular receptors in which extracellular inputs can be used to...; 29. A RNA-TARGETED PLATFORM FOR GENETIC PROGRAMMING AND METHODS OF USING SUCH SYSTEM; 30. AN "ON" SWITCH DESIGN AS A PHARMACOLOGICAL METHOD TO CONTROL CHIMERIC ANTIGEN RECEPTOR ACTIVITY FOR CELL-BASED IMMUNOTHERAPIES ("ON-SWITCH CHIMERIC

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. allogene, scifi foods

    Legal Proceedings:

    1. NONE

  13. Michael R. Wilson, MD* and
    14. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaking honoraria from Genentech, Takeda, WebMD and Novartis.

    Editorial Boards:

    1. NONE

    Patents:

    1. 1. Patent pending for Kelch-like protein 11 (KLHL11) IgG as a marker of neurological autoimmunity.2. Patent pending for method for high percentage recovery of rare cells.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Roche/Genentech, Novartis

    Research Support, Government Entities:

    1. 1. National Institute of Neurological Disorders and Stroke, K08 NS096117, PI, 2016-20212. National Institute of Allergy and Infectious Diseases, R01AI145437, PI, 2019-20243. National Institute of Neurological Disorders and Stroke, U01NS120836, Co-PI, 2021-20264. National Institute of Neurological Disorders and Stroke, R01NS125693, Co-PI, 2022-20265. National Institute of Allergy and Infectious Diseases, R01AI158861, Co-I, 2021-20266. National Institute of Mental Health, R01MH122471, Co-PI, 2020-20257. National Institute of Allergy and Infectious Diseases, U19AI077439, Co-I, 2021-20238. National Institute of Neurological Disorders and Stroke, R35NS111644, Co-I, 2019-2027

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Sandler Foundation2. William K. Bowes, Jr. Foundation3. Westridge Foundation4. UCSF Weill Institute for Neurosciences5. Marcus Foundation7. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. 1. VeriPhi Health, 20222. Delve Bio, 2022

    Legal Proceedings:

    1. NONE

  14. Scott S. Zamvil, MD, PhD*
    15. Scientific Advisory Boards:

    1. Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. Foundation.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Biogen - Speaker honoraria and advisory board meetings(2) Teva - Speaker honoraria and advisory board meetings(3) Alexion - Speaker honoraria and advisory board meetings(4) Novartis - Speaker honoraria and advisory board meetings(5) Horizon - Speaker honoraria and advisory board meetings

    Editorial Boards:

    1. (1) Neurology, Neuroimmunology and Neuroinflammation,Deputy Editor, 2014-present

    Patents:

    1. "Aquaporin-4 peptides and methods for using same"(SF2010-074; USF-461PRV (pending). The applicationdescribes the discovery of aquaporin-4 T cell determinantsin neuromyelitis optica patients and the use forantigen-specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis, Genentech/Roche, Horizon and Alexion.

    Speakers' Bureaus:

    1. Advanced Health Media, 2009-presentBiogen, 2009-presentAlexion, 2019-presentViela Bio, 2020Horizon, 2021-present

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen - speaker and advisory board meetings(2) Teva - speaker and advisory board meetings(3) Genentech - advisory board meeting(4) Novartis - advisory board meetings(5) Genzyme - advisory board meetings(6) Alexion - advisory board meeting(7) Horizon - advisory board meetings

    Research Support, Government Entities:

    1. NIH RO1 AI131624-O1A1NIH R21 NS10815990-01

    Research Support, Academic Entities:

    1. NMSS RG 1701-26628NMSS RG 1801-29861

    Research Support, Foundations and Societies:

    1. Alexander M. and June L. Maisin Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (S.G., S.A.S., C.S., R.D., S.L.H., M.R.W., S.S.Z.), Weill Institute for Neurosciences, University of California San Francisco, CA; Department of Cellular Molecular Pharmacology (M.S., J.D., W.L.), University of California San Francisco Cell Design Institute, CA; Veterans Affairs Health Care System (R.A.S.), Department of Pathology, Stanford University School of Medicine, CA; Departments of Neurology and Pathology and Immunology (G.F.W.), Washington University in St. Louis, MO; and Chan Zuckerberg Biohub (W.W., J.E.P.), San Francisco, CA.
  1. Correspondence
    Dr. Zamvil zamvil{at}ucsf.neuroimmunol.org
View Full Text

Article usage

Article usage: January 2023 to February 2023

AbstractFullPdfSource
Jan 2023181696367Highwire
Feb 202332572273Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me